MULTIPLE SCLEROSIS

Precision DMT Matching
for Multiple Sclerosis

MSProfile™ identifies whether you're Th1, Th17, or B-cell dominant—so you start with the high-efficacy DMT most likely to work for YOUR MS.

The First-Line Therapy Problem

Standard MS treatment starts with first-line DMTs like Copaxone or Avonex. If those fail after 12-18 months, you escalate to high-efficacy therapies. Meanwhile, new lesions form and disability progresses.

What Patients Face:

  • 18+ months on ineffective first-line therapy
  • New lesions and disability progression during this time
  • Permanent neurological damage that can't be reversed
  • Delayed access to the DMT that would have worked

The PathwayBio Solution

Test your neuroinflammatory pathways at diagnosis. If you're B-cell dominant, start Ocrevus immediately. If you're Th17-driven, consider Mavenclad. Don't waste 18 months on therapies that won't stop YOUR disease.

Choose Your Testing Package

Select the level of analysis that's right for your MS

FOR MOST PATIENTS

MSProfile™

Core Panel

$395

One-time payment

What's Included:

  • 35+ biomarkers analyzed
  • IL-17A, IL-23, IFN-γ, IL-6 pathways
  • Neurofilament Light Chain (disease activity)
  • JC virus antibodies (PML risk)
  • MOG, AQP4 antibodies (differential dx)
  • DMT matching (Ocrevus, Tysabri, Mavenclad)

Best For:

Newly diagnosed patients or those considering escalation to high-efficacy DMTs.

Full Details →
COMPREHENSIVE

MSProfile Plus™

Enhanced Panel

$595

One-time payment

Everything in Core PLUS:

  • 53 total biomarkers
  • B-cell analysis (CD19+, memory B-cells)
  • GFAP, Tau (neurodegeneration markers)
  • BAFF/BLyS, CXCL13 (B-cell factors)
  • Oxidative stress markers
  • BBB integrity assessment

Best For:

Highly active MS, failed multiple DMTs, or considering HSCT/Lemtrada.

Full Details →

Start with the Right DMT from Day One

Don't waste time on first-line therapies that won't work for YOUR MS pathways.

Order Your Panel →
EOFMS echo "MS landing page created successfully"